

FDA APPROVES NEW TREATMENT FOR ADVANCED PROSTATE CANCER PATIENTS

Written by Zero - the end of prostate cancer
Monday, 20 May 2013 14:21

- [Discount - Adobe Photoshop CS5 Extended MAC](#)
- [Download Autodesk AutoCAD Raster Design 2009](#)
- [Discount - Autodesk Showcase 2011](#)
- [Buy OEM Autodesk 3ds Max 2011](#)
- [Download Microsoft Streets & Trips 2011](#)
- [Buy OEM Microsoft Money 2007 Home & Business](#)
- [Buy Cheap Avid Media Composer 5](#)
- [Download Hazel 3](#)
- [Buy OEM Nuance PDF Converter Professional 5](#)
- [Buy Sony Movie Studio Platinum 12 \(en,fr,de,ja,ru,es\)](#)
- [Buy Adobe CC Master Collection MAC \(Full LifeTime License\) \(en\)](#)
- [Buy OEM Lynda.com - Photoshop for Designers: Shape Layers](#)
- [Buy Cheap Sony Vegas Movie Studio HD Platinum 11](#)

The FDA has approved Bayer and Algeta's drug Xofigo (radium Ra 223 dichloride, formerly known as alpharadin) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues. It is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.

Patients who are interested in finding out where and when newly FDA approved drug Xofigo will be available can call 1-855-696-3446 (1-855-6Xofigo) or visit the website www.xofigo.com.